Prot #R668-AD-1539: A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged ≥ 6 Months to < 6 Years with Severe Atopic Dermatitis

Project: Research project

Project Details

StatusActive
Effective start/end date12/4/1712/4/23

Funding

  • ICON Clinical Research Limited (Prot #R668-AD-1539)
  • Regeneron Pharmaceuticals, Inc. (Prot #R668-AD-1539)